---

Kurzfassung

The new circular RNA enables specific binding and inhibition of heterogeneous nuclear ribonucleoprotein L in cells and thus opens new therapeutic approaches for the treatment of pancreatic and other cancer types, where hnRNP L is deregulated.

---

Hintergrund

The new circular RNA is very stable, it can easily be transfected into cells. It is used to sponge and thereby inhibit selectively hnRNP L.

---

Bilder & Videos

---

Lösung

A new artificial circular RNA with an unusual ribonucleotide sequence was designed to bind and inhibit intracellular heterogeneous nuclear ribonucleoprotein L (hnRNP L). HnRNP L plays an essential role in the development of pancreatic and other cancer types.

---

Vorteile

• Circular RNA is much more stable than the corresponding linear RNA.
• Circular RNA can be designed to sponge RNA-binding proteins, thereby inhibiting the metabolic function of such proteins.
• Circular RNA can easily be introduced into cells and has no adverse side effects.
• A circular RNA was designed to bind hnRNP L with high specificity and affinity, inactivating this protein and thus opening up new therapy options for pancreatic and other cancer types, where hnRNP L is deregulated.

---

Anwendungsbereiche

The new circular RNA is useful in pancreatic and oral squamous cell cancer therapy, when hnRNP L is overexpressed, based on binding and inhibiting intracellular heterogeneous nuclear ribonucleoprotein L (hnRNP L).

---

Service

On behalf of its shareholder Justus-Liebig-Universität Giessen TransMIT GmbH is looking for cooperation partners or licensees for further development in Germany, Europe, US, and Asia.